The following IPOs are expected to price this week:
CareDx (CDNA), which sells molecular diagnostic tests to monitor heart transplants, plans to raise $50 million by offering 3.1 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, CareDx would command a market value of $175 million. CareDx, which was founded in 1998, booked $23 million in sales over the last 12 months. The Brisbane, CA-based company plans to list on the NASDAQ under the symbol CDNA. Piper Jaffray and Leerink Partners are the joint bookrunners on the deal.
Globant (GLOB), an Argentina-based IT outsourcer focused on mobile, cloud and big data, plans to raise $76 million by offering 6.3 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Globant would command a market value of $400 million. Globant, which was founded in 2003, booked $167 million in sales over the last 12 months. The Luxembourg-based company plans to list on the NYSE under the symbol GLOB. J.P. Morgan, Citi and Credit Suisse are the joint bookrunners on the deal.
iRadimed (IRMD), which makes non-magnetic MRI-safe IV infusion pumps, plans to raise $10 million by offering 1.8 million shares at a price range of $5.00 to $6.00. At the midpoint of the proposed range, iRadimed would command a market value of $64 million. iRadimed, which was founded in 1992, booked $12 million in sales over the last 12 months. The Winter Park, FL-based company plans to list on the NASDAQ under the symbol IRMD. Roth Capital is the lead bookrunner on the deal.
Medical Transcription Billing (MTBC), which provides a SaaS platform for ambulatory care facilities, plans to raise $30 million by offering 3.0 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Medical Transcription Billing would command a market value of $98 million. Medical Transcription Billing, which was founded in 2001, booked $11 million in sales over the last 12 months. The Somerset, NJ-based company plans to list on the NASDAQ under the symbol MTBC. Chardan Capital Markets, Aegis Capital Corp. and Summer Street Research Partners are the joint bookrunners on the deal.
Microlin Bio (MCLB), a diagnostic and therapeutics biotech focusing on microRNA and its role in oncology, plans to raise $28 million by offering 5.5 million shares at a price range of $4.50 to $5.50. At the midpoint of the proposed range, Microlin Bio would command a market value of $51 million. Microlin Bio, which was founded in 2013, booked $0 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol MCLB. Brean Capital and Summer Street Research Partners are the joint bookrunners on the deal. (Revised terms for the fourth time on 7/3/2014. Originally planned to offer 3.6 million common shares at a range of $6-$8.)
Pfenex (PFNX), which is developing a biosimilar version of Roche's Lucentis treatment for wet AMD, plans to raise $65 million by offering 5.0 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Pfenex would command a market value of $198 million. Pfenex, which was founded in 2009, booked $11 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NYSE under the symbol PFNX. William Blair and JMP Securities are the joint bookrunners on the deal.
Roka Bioscience (ROKA), which develops food safety testing equipment that uses molecular diagnostics, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Roka Bioscience would command a market value of $272 million. Roka Bioscience, which was founded in 2009, booked $3 million in sales over the last 12 months. The Warren, NJ-based company plans to list on the NASDAQ under the symbol ROKA. BofA Merrill Lynch, Leerink Partners, Cowen & Company and Wedbush PacGrow are the joint bookrunners on the deal.
Sage Therapeutics (SAGE), a biotech developing treatments for life-threatening seizures, plans to raise $60 million by offering 4.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Sage Therapeutics would command a market value of $382 million. Sage Therapeutics, which was founded in 2010, booked $0 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol SAGE. J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal.
TerraForm Power (TERP), a spinoff of SunEdison that owns contracted solar power assets, plans to raise $401 million by offering 20.1 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, TerraForm Power would command a market value of $2.0 billion. TerraForm Power, which was founded in 2014, booked $26 million in sales over the last 12 months. The Beltsville, MA-based company plans to list on the NASDAQ under the symbol TERP. Goldman Sachs, Barclays, Citi and J.P. Morgan are the joint bookrunners on the deal.
Trupanion (TRUP), which provides medical insurance covering cats and dogs in North America, plans to raise $100 million by offering 7.1 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Trupanion would command a market value of $429 million. Trupanion, which was founded in 2000, booked $92 million in sales over the last 12 months. The Seattle, WA-based company plans to list on the NYSE under the symbol TRUP. RBC Capital Markets, Barclays and Stifel are the joint bookrunners on the deal.
TubeMogul (TUBE), which provides a programmatic digital video ad buying platform for brand advertisers, plans to raise $75 million by offering 6.3 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, TubeMogul would command a market value of $394 million. TubeMogul, which was founded in 2007, booked $70 million in sales over the last 12 months. The Emeryville, CA-based company plans to list on the NASDAQ under the symbol TUBE. BofA Merrill Lynch, Citi and RBC Capital Markets are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
